Overview
McDermott Will & Emery advised Relyens Innovation Santé / Turenne Capital and UI Investissement on the acquisition of a stake in AlgoTx, a european biotech that develops a first-in-class treatment ATX01 for chemotherapy- induced peripheral neuropathy (CIPN).
Historical investors, Bpifrance through its Innobio 2 fund and Omnes Capital also participated in this fundraising. Early and new business angel investors also significantly participated in this financing round.
The proceeds will be used to demonstrate the clinical efficacy of ATX01 in neuropathic pain.
The McDermott team that advised Relyens Innovation Santé / Turenne Capital and UI Investissement was composed of :
• Anthony Paronneau, partner, Lucie Martin and Alice Sevestre, associates
